$BCTX to showcase six clinical data presentations at ASCO 2026, including final randomized Phase 2 Bria-IMT survival and quality of life data plus biomarker analyses from its ongoing Phase 3 study. A major catalyst to watch as the company advances. https://globenewswire.com/news-release/2026/0...-2026.html
